- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05337566
Minskar ytterligare användning av preoperativ azitromycin posthysterektomiinfektioner
Infektioner efter hysterektomi - en placebokontrollerad studie som jämför profylaktisk användning av azitromycin och cefuroxim med enstaka cefuroxim
During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Päivi K Rahkola-Soisalo, Adj prof,MD
- Telefonnummer: +358504270411
- E-post: paivi.rahkola-soisalo@hus.fi
Studera Kontakt Backup
- Namn: Ninja Savonius, MD
- Telefonnummer: +358503466986
- E-post: ninja.savonius@hus.fi
Studieorter
-
-
-
Helsinki, Finland
- Rekrytering
- Helsinki University Central Hospital
-
Kontakt:
- Ninja Savonius, MD
- Telefonnummer: +358503466986
- E-post: ninja.savonius@hus.fi
-
Kontakt:
- Päivi K Rahkola-Soisalo, Adj prof,MD
- Telefonnummer: +358 50 4270411
- E-post: paivi.rahkola-soisalo@hus.fi
-
Underutredare:
- Liisu Saavalainen, PhD, MD
-
Underutredare:
- Päivi Härkki, Adj prof, MD
-
Underutredare:
- Tomi Mikkola, Prof, MD
-
Underutredare:
- Veli-Jukka Anttila, Adj prof,MD
-
Underutredare:
- Seppo Virtanen, DI, MD
-
Underutredare:
- Anne Saloranta, Adj Prof
-
Underutredare:
- Ilkka Kalliala, Adj Prof, MD
-
Underutredare:
- Suvi Niku, PhD, MD
-
Jyväskylä, Finland, 40620
- Rekrytering
- Jyväskylä Central Hospital
-
Kontakt:
- Jaana Seikkula, PhD
- Telefonnummer: +358 41 548 3562
- E-post: jaana.seikkula@fimnet.fi
-
Kuopio, Finland, 70029
- Rekrytering
- Kuopio University Central Hospital
-
Kontakt:
- Henna Kärkkäinen, PhD
- Telefonnummer: +358 44 7172741
- E-post: henna.karkkainen@kuh.fi
-
Oulu, Finland, PL23
- Rekrytering
- Oulu University Central Hospital
-
Kontakt:
- Sari Koivurova, PhD
- Telefonnummer: +358 8 3150211
- E-post: sari.koivurova@ppshp.fi
-
Tampere, Finland, 33521
- Rekrytering
- Tampere University Central Hospital
-
Kontakt:
- Riikka Niemi, PhD
- Telefonnummer: +358 3 31169083
- E-post: riikka.niemi@pshp.fi
-
Underutredare:
- Elina Ylilehto, PhD, MD
-
Turku, Finland
- Rekrytering
- Turku University Central Hospital
-
Kontakt:
- Pia Heinonen, PhD
- Telefonnummer: +358 2 313 5002
- E-post: pia.heinonen@tyks.fi
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Women undergoing hysterectomy for benign indication in University Hospitals (Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital and Kuopio University Hospital) who have not any contraindications for azithromycin or cefuroxime.
Exclusion Criteria:
- Inability to understand the study protocol.
- Allergy for either cefuroxime or azithromycin.
- Congenital or acquired prolonged Q-T-corrected interval. All the participants will be asked about arrhythmias and whether they have congenital arrhythmias in the family,
- Electrocardiogram will be checked for all the participants.
- Use of medicines that may prolong Q-T-corrected interval (class Ia arrhythmia medications, quinidine, procainamide, and class III arrhythmia medications dofetilide, amiodarone and sotalol).
- Use of selective serotonin reuptake inhibitor medication and prolonged Q-T-corrected interval.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Azithromycin + Cefuroxime
Changed with renewed study permissions: These patients will receive Azithromycin 500 mg (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more) in the operating theatre before the incision. The previous description: These patients will receive Azithromycin 500 mg (2 tablets) per orally in the evening before the operation and single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision. |
Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision |
|
Aktiv komparator: Placebo + Cefuroxime
Changed with new study permissions: These patients will receive placebo (2 tablets) per orally on the operation day when they arrive to the hospital and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose bosy mass index is 30 or more)in the operating theatre before the incision. The previous description: These patients will receive placebo (2 tablets) per orally in the evening before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision. |
Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of post-hysterectomy episodes with deep infections
Tidsram: Deep infections that occur between the first and 30th postoperative day after hysterectomy
|
Number of deep wound and pelvic organ infection episodes reported by patients and doctors |
Deep infections that occur between the first and 30th postoperative day after hysterectomy
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of other post-hysterectomy infections or fever episodes
Tidsram: Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.
|
Number of superficial infections, other infections, such has urine tract infections, or fever episodes lasting over 38 ℃ over 2 days |
Number of other infections or fever episodes that occur between the first and 30th postoperative day after hysterectomy.
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Päivi Rahkola-Soisalo, Adj prof, MD, Helsinki University Central Hospital
- Studiestol: Tomi Mikkola, Prof, MD, Helsinki University Central Hospital
- Studierektor: Päivi Rahkola-Soisalo, Adj prof, MD, Helsinki University Central Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HUS/117/2022
- 2021-003467-10 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .